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Abstract
Background:	The	current	standard	of	care	(SOC)	for	pediatric	venous	thromboembo-
lism	(VTE)	comprises	unfractionated	heparin	(UFH),	or	low-	molecular-	weight	heparin	
(LMWH)	followed	by	LMWH	or	vitamin	K	antagonists,	all	of	which	have	limitations.	
Dabigatran	etexilate	 (DE)	has	demonstrated	efficacy	and	safety	for	adult	VTE	and	
has	the	potential	to	overcome	some	of	the	limitations	of	the	current	SOC.	Pediatric	
trials	are	needed	to	establish	dosing	in	children	and	to	confirm	that	results	obtained	
in	adults	are	applicable	in	the	pediatric	setting.
Objectives:	To	describe	the	design	and	rationale	of	a	planned	phase	IIb/III	trial	that	
will	evaluate	a	proposed	dosing	algorithm	for	DE	and	assess	the	safety	and	efficacy	
of	DE	versus	SOC	for	pediatric	VTE	treatment.
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1  | INTRODUCTION
Venous	thromboembolism	(VTE)	in	children	is	associated	with	con-
siderable	morbidity	and	mortality.1	The	overall	annual	incidence	of	
VTE	 in	 the	pediatric	population	 is	 approximately	0.07-	0.14	events	
per	10	000	children,	but	this	number	is	increasing,2–4 which may be 
explained	by	 improved	detection	of	previously	undiagnosed	cases,	
increased	awareness	of	VTE	in	children	in	pediatric	hospitals,	more	
frequent	use	of	central	venous	lines	(which	is	the	most	common	risk	
factor	for	VTE	in	younger	children),	and	improved	survival	from	pre-
viously	fatal	conditions.4,5
The	 current	 standard	 of	 care	 (SOC)	 in	 pediatric	 VTE	 is	 initial	
treatment	 with	 unfractionated	 heparin	 (UFH)	 or	 low-	molecular-	
weight	heparin	(LMWH),	then	followed	by	LMWH	or	vitamin	K	an-
tagonists	 (VKA).6–8	 However,	 all	 of	 these	 agents	 have	 limitations;	
LMWH,	 for	 example,	 is	 administered	 by	 subcutaneous	 injection,	
which	may	be	a	burden	 for	both	children	and	caregivers,	whereas	
VKAs	require	coagulation	monitoring,	and	are	associated	with	drug–
drug	and	drug–food	interactions,	which	hamper	the	time	within	the	
therapeutic	target	range.5,6,8
Treatment	 recommendations	 for	 children	 are	 similar	 to	 those	
for	adults	and	are	based	on	extrapolation	of	data	from	adult	clinical	
trials.8	 Nevertheless,	 there	 are	 important	 differences	 to	 consider	
with	 regard	 to	 VTE	 epidemiology	 and	management	 in	 adults	 and	
children	 (especially	 in	 very	 young	 children).	 First,	 unlike	 in	 adults,	
VTEs	 in	 children	 usually	 occur	 secondarily	 to	 another	 identifiable	
risk	 factor,	most	 commonly	 the	presence	of	 a	 central	 venous	 line,	
particularly	 in	neonates	and	 infants.	Other	risk	factors	 include	un-
derlying	conditions	such	as	cancer	or	congenital	heart	disease.2,8,9 
Second,	 there	 are	 age-	related	 differences	 in	 the	 hemostatic	 and	
coagulation	systems	that	affect	the	pathophysiology	of	thrombosis	
and	the	effects	of	anticoagulant	treatments.7,8,10	Finally,	distribution,	
binding,	and	clearance	of	drugs	can	all	be	affected	by	age;	for	exam-
ple,	when	dosing	renally	excreted	drugs	in	children,	kidney	matura-
tion	must	be	considered.8,11	Given	these	differences,	application	of	
adult	treatment	recommendations	to	children	may	be	inappropriate.	
Consequently,	it	is	necessary	to	conduct	pharmacologic	evaluations	
of	anticoagulants,	specifically	in	pediatric	patients.7,10
The	direct	thrombin	inhibitor	dabigatran,	which	is	orally	adminis-
tered	 as	 the	 prodrug	 dabigatran	 etexilate	 (DE),12	 has	 demonstrated	
efficacy	and	safety	in	adults	with	VTE	and	may	overcome	some	of	the	
limitations	associated	with	current	SOC	(UFH,	LMWH,	and	VKA).12–14 
In	addition,	the	mechanism	of	action	of	DE	is	independent	of	endog-
enous	thrombin,	 levels	of	which	are	physiologically	 lower	in	children	
Patients/Methods:	 An	 open-	label,	 randomized,	 parallel-	group	 noninferiority	 study	
will	be	conducted	in	approximately	180	patients	aged	0	to	<18	years	with	VTE,	who	
have	 received	 initial	 UFH	 or	 LMWH	 treatment	 and	 who	 are	 expected	 to	 require	
≥3	months	of	anticoagulation	therapy.	Patients	will	receive	DE	or	SOC	for	3	months.	
DE	will	be	administered	twice	daily	as	capsules,	pellets,	or	an	oral	liquid	formulation	
according	 to	 patient	 age.	 Initial	 doses	 will	 be	 calculated	 using	 a	 proposed	 dosing	
algorithm.
Results:	There	will	be	two	coprimary	endpoints:	a	composite	efficacy	endpoint	com-
prising	the	proportion	of	patients	with	complete	thrombus	resolution,	freedom	from	
recurrent	VTE	and	VTE-	related	mortality,	and	a	safety	endpoint:	freedom	from	major	
bleeding	events.
Conclusion:	 Findings	will	 provide	 valuable	 information	 regarding	 the	 efficacy	 and	
safety	of	DE	for	the	treatment	of	pediatric	VTE.	ClinicalTrials.gov	registration	num-
ber:	NCT01895777.
K E Y W O R D S
anticoagulants,	dabigatran	etexilate,	direct	thrombin	inhibitors,	pediatrics,	venous	
thromboembolism
Essentials
•	 Current	standard	of	care	(SOC)	for	pediatric	venous	thromboembolism	(VTE)	has	limitations.
•	 Dabigatran	etexilate	(DE)	versus	SOC	will	be	studied	in	children	with	VTE	in	a	phase	IIb/III	trial.
•	 A	dosing	algorithm	for	DE	in	children	will	be	assessed	guiding	dosing.
•	 Valuable	data	on	the	safety	and	efficacy	of	DE	for	VTE	in	children	will	be	obtained.
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than	adults,	thus	offering	a	potential	benefit	over	UFH/LMWH,	which	
act by directly binding antithrombin.6	To	date,	 findings	 from	studies	
conducted	in	children	and	adolescents	are	comparable	to	those	seen	
in	 adults	 in	 terms	 of	 safety	 and	 pharmacokinetic	 (PK)/pharmacody-
namic	(PD)	relationships	(Table	1).15–17	Moreover,	because	dabigatran	
is	 predominately	 excreted	 renally,18	 dosing	 according	 to	 renal	 func-
tion	may	lead	to	comparable	exposure	between	adults	and	pediatric	
patients.19
2  | OBJEC TIVE
The	objective	of	the	current	manuscript	is	to	describe	the	rationale	
and	design	of	a	study,	the	aim	of	which	is	to	evaluate	the	appropri-
ateness	of	a	proposed	DE	dosing	algorithm	in	pediatric	patients	aged	
between	0	and	<18	years	and	to	assess	the	safety	and	efficacy	of	DE	
versus	SOC	for	the	treatment	of	VTE	in	this	patient	group.
3  | MATERIAL S AND METHODS
This	is	a	phase	IIb/III,	noninferiority,	open-	label,	randomized,	parallel-	
group	study	that	will	be	conducted	 in	~100	sites	 in	~30	countries.	
The	trial	is	sponsored	by	Boehringer	Ingelheim.	An	independent	data	
monitoring	committee	(DMC)	will	assess	the	safety,	tolerability,	and	
efficacy,	and	will	provide	recommendations	to	the	sponsor	regard-
ing	continuation,	modification,	or	termination	of	the	study.	A	central	
independent	adjudication	committee,	which	will	be	blinded	to	treat-
ment	groups,	will	evaluate	all	elements	of	the	coprimary	endpoints	
and	confirm	or	refute	outcome	events.	Scientific	leadership	regard-
ing	study	design	and	conduct	will	be	provided	by	a	steering	commit-
tee.	The	administrative	structure	of	the	trial	is	shown	in	Figure	1.
The	 target	 population	 will	 comprise	male	 and	 female	 patients	
aged	0-	17	years	with	an	objectively	confirmed	diagnosis	of	VTE	(eg,	
deep	vein	thrombosis,	pulmonary	embolism,	and/or	cerebral	venous	
sinus	 thrombosis).	 Individuals	who	 have	 received	 initial	 parenteral	
treatment	 with	 UFH	 or	 LMWH	 for	 a	 minimum	 of	 5	days	 (usually	
5-	7	days	and	no	 longer	than	21	days)	and	who	are	expected	to	re-
quire	anticoagulation	therapy	for	at	least	3	months	(including	an	ini-
tial	parenteral	phase)	will	be	eligible	for	study	inclusion.	A	list	of	all	
inclusion	and	exclusion	criteria	is	provided	in	Table	2.
Patients	will	 be	 stratified	 into	 three	age	groups:	 stratum	1	 (12	
to	 <18	years),	 stratum	 2	 (2	 to	 <12	years),	 and	 stratum	 3	 (birth	 to	
<2	years);	recruitment	will	begin	in	stratum	1	then	proceed	to	strata	
2	and	3	based	on	recommendations	from	the	DMC.	The	study	will	
be	conducted	in	accordance	with	the	Declaration	of	Helsinki20 and 
will	be	approved	by	an	institutional	review	board/independent	eth-
ics	committee	and	a	competent	authority	according	to	national	and	
international	 regulations.	 Written	 informed	 consent	 must	 be	 ob-
tained	from	patients	or	their	legal	representatives	according	to	the	
International	Conference	on	Harmonisation	Good	Clinical	Practice21 
and	 the	 regulatory	 and	 legal	 requirements	 of	 each	 participating	
country.	The	 trial	will	be	conducted	according	 to	 the	principles	of	
Good	Clinical	Practice.	Trial-	related	monitoring,	audits,	institutional	
TABLE  1 Clinical	studies	of	DE	in	pediatric	subjects
Study Objective Age of subjects Findings
NCT0084441516 Phase	IIa	trial	to	assess	the	safety,	PK,	and	PD	of	
DE	capsules	bid	for	3	days	after	standard	
anticoagulant	therapy	for	treatment	of	primary	
VTE.	Patients	initially	received	1.71	(±10%)	
mg/kg	(80%	of	a	150	mg/70	kg	bid	adult	dose),	
followed	by	2.14	(±10%)	mg/kg	(target	adult	
dose	adjusted	for	patient’s	weight).
12-	<18	years	(n =	9) DE	was	generally	well	tolerated	apart	from	
two	cases	of	mild	dyspepsia.	The	PK/PD	
relationship	was	comparable	to	that	seen	in	
adults;	the	relationship	between	dabigatran	
plasma	concentration	was	linear	for	dTT	and	
ECT	and	nonlinear	for	aPTT.
NCT0108373215 Phase	IIa	study	to	assess	PK,	PD,	safety,	and	
tolerability	of	a	single	dose	of	an	oral	solution	
of	DE,	following	standard	anticoagulant	
therapy	for	treatment	of	VTE.	DE	was	
administered	at	a	weight-	and	age-	adjusted	
dose	(calculated	using	a	nomogram)	equivalent	
to	150	mg	bid	in	adults.
1-	<12	years:	Two	groups:	
1-	<2	years	(n	=	6);	
2-	<12	years	(n	=	12)
The	projected	steady-	state	dabigatran	trough	
concentrations	were	largely	comparable	to	
those	seen	in	adult	patients.12	A	linear	PK/
PD	relationship	was	observed	for	ECT	and	
dTT;	nonlinear	relationships	were	seen	for	
aPTT;	PK/PD	relationships	were	comparable	
to	those	in	adults	and	adolescents.	The	oral	
solution	of	DE	was	well	tolerated.
NCT0222326017 Phase	IIa	study	to	assess	PK,	PD,	safety,	and	
tolerability	of	a	single	dose	of	DE	oral	solution	
(based	on	weight-	and	age-	adjusted	nomogram)	
given	after	standard	anticoagulant	therapy	in	
neonates	with	VTE.
Birth	to	<1	year	(n	=	8) The	projected	steady-	state	dabigatran	trough	
concentrations	were	largely	comparable	to	
those	observed	in	adult	patients.12	A	linear	
PK/PD	relationship	was	observed	for	ECT	
and	dTT;	nonlinear	relationships	were	seen	
for	aPTT;	PK/PD	relationships	were	
comparable	to	those	in	adults	and	adoles-
cents.	The	oral	solution	of	DE	was	well	
tolerated.
aPTT,	activated	partial	thromboplastin	time;	bid,	twice	daily;	DE,	dabigatran	etexilate;	dTT,	diluted	thrombin	time;	ECT,	ecarin	clotting	time;	PD,	phar-
macodynamics;	PK,	pharmacokinetics;	VTE,	venous	thromboembolism.
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review	board/independent	ethics	committee	review,	and	regulatory	
inspections	will	be	performed	to	verify	the	accuracy	of	the	data.
Patients	will	be	randomized	2:1	to	receive	DE	or	SOC	with	LMWH	
or	 VKA.	 Randomization	 will	 be	 managed	 by	 Interactive	 Response	
Technology.	DE	will	be	administered	twice	daily	(bid)	as	capsules,	pel-
lets,	or	an	oral	liquid	formulation	depending	on	the	age	of	the	patient	
and	their	ability	to	swallow	capsules	or	pellets.	Capsules	will	be	given	
to	patients	aged	8-	18	years	who	are	able	to	swallow	capsules;	pellets	
will	be	given	to	patients	aged	6	months	to	<8	years	(and	those	aged	
≥8	to	<12	years	who	are	unable	 to	swallow	capsules);	an	oral	 liquid	
formulation	will	be	administered	to	patients	aged	0	to	<6	months	(and	
those	aged	6	to	<12	months	who	are	unable	to	take	pellets).
According	to	guidance	from	the	US	Food	and	Drug	Administration	
(FDA),	 findings	on	drug	efficacy	may	be	extrapolated	from	adults	to	
children	if	the	course	of	a	disease	and	the	effects	of	a	particular	drug	
treatment	 are	 similar	 between	 the	 two	populations.22	Although	dif-
ferences	exist	in	the	pathophysiology	of	pediatric	and	adult	VTE9 the 
principal	pathological	causes	outlined	in	the	Virchow	triad	(vessel	wall	
abnormality,	blood	flow	disturbances,	and	coagulability	of	the	blood)	
largely	apply	to	both.	PD	data	obtained	from	previous	studies	indicate	
that	 the	response	to	dabigatran	 in	children	 is	similar	 to	that	seen	 in	
adults.15,17,23,24	Based	on	these	similarities	and	in	line	with	FDA	guide-
lines,	it	was	considered	reasonable	to	assume	that	DE	will	be	effective	
in	pediatric	patients.
It	is	generally	accepted	and	recommended	by	regulatory	agencies	
that	pediatric	dosing	should	lead	to	exposure	comparable	to	that	of	
adult	levels,	if	a	similar	PK/PD	relationship	has	been	demonstrated.25 
Data	from	an	in	vitro	study,	previous	phase	II	pediatric	VTE	studies	
of	dabigatran,	and	a	subsequent	pooled	analysis	of	pediatric	PK/PD	
data,	demonstrate	that	the	PK/PD	relationship	observed	in	pediat-
ric	patients	(from	birth	to	<18	years	old)	was	fairly	consistent	across	
ages,	with	 the	exception	of	 those	aged	<1	month,	 and	was	 similar	
to	that	seen	in	adults	with	VTE.15,17,23,24	Therefore,	for	the	current	
study	it	was	deemed	appropriate	to	target	dabigatran	exposure	lev-
els	shown	to	be	effective	in	the	adult	population.
Age	determines	the	renal	function	of	a	child,	which	is	essential	
for	 the	 dosing	 of	DE,	 and	 therefore	 the	 dosing	 in	 children	 differs	
from	adult	 dosing.	Whereas	 changes	 in	 renal	 function	 are	physio-
logical	across	 the	years	of	childhood,	maturation	of	 renal	 function	
is	completed	after	adolescence	allowing	for	simplified	fixed	dosing	
in	 healthy	 adults.	 Dosing	 based	 on	 Hayton’s	 formula19	 accounts	
for	 the	maturation	of	 renal	 function	across	 childhood,	 resulting	 in	
a	more	 individualized	 dosing	 algorithm	 in	 children.	 As	 renal	 func-
tion	 in	children	and	adolescents	 is	 relatively	higher	 than	 in	adults,	
dose	 estimations	were	 based	 on	 a	 young	 adult	 patient	 (reference	
patient:	20	years	old;	70	kg)	whose	renal	function	more	closely	re-
sembled	 that	of	 the	 target	pediatric	population.	Hayton	predicted	
a	glomerular	filtration	rate	of	136	mL/min	for	a	20-	year-	old	patient	
of	70	kg	body	weight.19	To	achieve	the	median	trough	exposure	as	
observed	 in	 a	 typical	 adult	 patient	 given	 dabigatran	 150	mg	 bid,	
the	20-	year-	old	reference	patient	would	need	to	receive	a	dose	of	
300	mg	bid.	This	dose	and	reference	patient	was	used	as	the	denom-
inator	to	derive	fractional	dosages	for	pediatric	patients	according	to	
a	child’s	estimated	renal	function.
F IGURE  1 Administrative	structure	of	the	trial.	CRO,	contract	research	organization;	DMC,	data	monitoring	committee;	OPU,	local	
Boehringer	Ingelheim	operating	unit;	PK,	pharmacokinetics;	PD,	pharmacodynamics;	TCM,	trial	clinical	monitor;	TMM,	team	member	
medicine.	*If	approved	by	the	sponsor,	a	local	laboratory	may	be	used	in	certain	circumstances	to	analyze	safety	samples;	PK	and	PD	plasma	
samples	may	be	analyzed	at	CROs.
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The	chosen	dosing	nomogram	based	on	Hayton’s	formula19	has	
been	 applied	 in	 previous	 pediatric	 phase	 IIa	 studies	 of	 DE.15,17 In 
these	studies,	dabigatran	exposure	achieved	with	the	dosing	nomo-
gram	in	VTE	patients	from	birth	to	12	years	of	age15,17	was	compara-
ble	to	that	seen	in	adult	patients,12	indicating	that	it	is	appropriate	to	
use	in	the	pediatric	population.
Initial	doses	are	expected	to	achieve	steady-	state	trough	concen-
trations	of	dabigatran	of	between	50	and	<250	ng/mL.	Thereafter,	
DE	may	be	titrated	up	or	down	(if	needed)	throughout	the	study	pe-
riod,	 to	maintain	steady-	state	trough	plasma	concentrations	within	
this	range.	The	chosen	lower	and	upper	limits	of	50	and	<250	ng/mL,	
respectively,	are	based	on	findings	in	adult	patients12,14,26–28	and	rep-
resent	a	range	in	which	a	beneficial	benefit-	risk	balance	is	expected.	
PK	simulations	show	that	a	bid	dosing	regimen	with	calculated	doses	
(with	a	maximum	330	mg	bid	starting	dose)	reduces	the	probability	
of	 trough	 levels	 falling	 below	 50	ng/mL	 and	 25	ng/mL	 to	 approxi-
mately	18%	and	3%,	respectively,	ie,	exposure	will	be	sufficient	for	
the	vast	majority	of	patients.
Levels	will	be	measured	within	the	first	week	of	dosing	to	poten-
tially	adjust	the	dose.	A	3-	month	treatment	period	(which	includes	the	
initial	parenteral	treatment	phase)	will	precede	a	1-	month	follow-	up	
phase.	At	the	follow-	up	visit,	patients	will	be	assessed	for	VTE.	Eligible	
patients	with	an	unresolved	clinical	 risk	 factor	at	 the	end	of	 the	3-	
month	 treatment	 period	may	 continue	 into	 study	NCT02197416,	 a	
phase	III,	single-	arm	study	of	DE	for	secondary	VTE	prevention	in	pa-
tients	aged	0	to	<18	years,	who	will	be	evaluated	for	up	to	12	months.
The	 coprimary	endpoints	 are	 as	 follows:	 (i)	 composite	 efficacy	
endpoint:	 the	proportion	of	patients	with	complete	 thrombus	 res-
olution,	 freedom	 from	 recurrent	 VTE	 (including	 symptomatic	 and	
asymptomatic,	 contiguous	 progression	 or	 noncontiguous	 new	
thrombus,	deep	vein	thrombosis,	pulmonary	and	paradoxical	embo-
lism	and	thrombus	progression)	and	freedom	from	VTE-	related	mor-
tality29;	and	(ii)	safety	endpoint:	freedom	from	major	bleeding	events	
defined	as	fatal	bleeding,	clinically	overt	bleeding	associated	with	a	
decrease	 in	hemoglobin	of	at	 least	20	g/L	 in	24	h,	bleeding	 that	 is	
retroperitoneal,	 pulmonary,	 intracranial	or	otherwise	 involving	 the	
central	nervous	system,	or	bleeding	that	requires	an	operation.29
All	components	of	the	coprimary	safety	and	efficacy	endpoints	
will	be	centrally	adjudicated	by	an	independent	blinded	committee.	
All	secondary	endpoints	and	other	assessments	are	listed	in	Table	3.	
Time	periods,	visits,	and	key	assessments	are	shown	in	Table	4.	The	
trial	aims	to	include	a	minimum	of	180	patients	who	will	be	evaluable	
for	the	coprimary	endpoints.	Recruitment	will	be	driven	by	opening	
new	sites	in	additional	countries,	to	ensure	that	the	minimum	num-
ber	of	patients	are	included.	Study	teams	will	also	be	encouraged	to	
increase	awareness	of	asymptomatic	pediatric	VTE.
3.1  | SAMPLE SIZE R ATIONALE AND 
ANALYSIS PL AN
The	efficacy	and	safety	coprimary	endpoints	will	be	tested	for	non-
inferiority	using	a	noninferiority	margin	of	20%	and	9%,	respectively,	
TABLE  2  Inclusion	and	exclusion	criteria
Inclusion criteria
Male	or	female	subjects	aged	0-	<18	years
Documented	diagnosis	of	VTE	(eg,	DVT,	PE,	central	line	thrombosis,	
sinus	vein	thrombosis),	initially	treated	with	parenteral	anticoagula-
tion,	eg,	UFH,	LMWH,	in	general	for	5-	7	days;	no	more	than	21	days
Anticipated	treatment	with	anticoagulants	for	VTE	for	at	least	
3	months	(including	initial	parenteral	treatment	period)
Written	informed	consent	from	parent/legal	guardian	and	agreement	
of	patient	(if	applicable)
Exclusion criteria
Conditions	associated	with	an	increased	risk	of	bleeding
Any	prior	intracranial	hemorrhage
Intracranial	or	intraspinal	surgeries	within	6	months	of	visit	2;	any	
other	major	surgery	within	4	weeks	of	visit	2
Any	major	planned	procedure	with	increased	risk	of	bleeding	within	
5	days	prior	to	study	treatment
History	of	intraocular,	spinal,	retroperitoneal,	or	atraumatic	
intra-	articular	bleeding	unless	cause	permanently	resolved
Gastrointestinal	hemorrhage	within	the	year	prior	to	screening	
unless	cause	permanently	resolved
History	of	gastroduodenal	ulcer	disease
History	of	hemorrhagic	disorder	or	bleeding	diathesis
Fibrinolytic	agents	within	48	h	of	DE	administration
Uncontrolled	hypertension	on	antihypertensive	treatment
Any	other	disease,	condition	or	intervention	with	increased	
bleeding	risk
Renal	dysfunction	(eGFR	<60	mL/min/1.73	m2	for	patients	aged	
12-	<18	years	or	eGFR	<80	mL/min/1.73	m2	for	patients	aged	
0-	<12	years	or	requirement	for	dialysis
Active	infective	endocarditis
Prosthetic	heart	valve	requiring	anticoagulation
Hepatic	disease
Active	liver	disease	including	active	hepatitis	A,	B,	and	C
Persistent	ALT	or	AST	or	AP	>	3	×	ULN	within	prior	3	months
Pregnant	or	breastfeeding.	Female	patients	who	have	reached	
menarche	but	not	using	contraceptive
Patients	in	stratum	3	(0-	<2	years)	with	gestational	age	at	birth	
<37	weeks	or	with	body	weight	lower	than	the	third	percentile
Anemia	(hemoglobin	<80	g/L)	thrombocytopenia	(platelet	count	
<80	×	109/L)	at	screening
Taken	prohibited	or	restricted	medication	within	1	week	of	the	first	
dose	of	study	medication	other	than	medication	for	prior	VTE	
treatment	and	P-	glycoprotein	inhibitors
Taken	an	investigational	drug	in	the	past	30	days
Allergic/sensitive	to	any	component	of	study	medication
Patients	or	parents/legal	guardians	considered	unreliable	to	
participate	or	any	condition	that	would	be	a	safety	hazard	to	the	
patients
Patients	or	parents/legal	guardians	unwilling	or	unable	to	undergo	or	
permit	repeat	of	baseline	imaging	tests	to	confirm	thrombus	
resolution	at	study	day	84	(or	at	early	end	of	treatment)	or	patients	in	
whom	such	repeat	tests	would	not	be	in	their	best	interest	medically
ALT,	 alanine	 aminotransferase;	 AP,	 alkaline	 phosphatase;	 AST,	 alanine	
aminotransferase;	DE,	dabigatran	etexilate;	DVT,	deep	vein	thrombosis;	
eGFR,	 estimated	 glomerular	 filtration	 rate;	 LMWH,	 low-	molecular-	
weight	heparin;	PE,	pulmonary	embolism;	UFH,	unfractionated	heparin;	
ULN,	upper	limit	of	normal;	VTE,	venous	thromboembolism.
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with	a	one-	sided	level	of	0.05.	Sample	size	was	justified	for	the	ef-
ficacy	coprimary	endpoint.	It	is	assumed	that	the	proportion	of	pa-
tients	with	complete	thrombus	resolution	and	no	recurrent	VTE	or	
VTE-	related	death	on	SOC	at	3	months	is	72%.30–40	Given	that	com-
plete	thrombus	resolution	is	expected	to	be	very	low	(eg,	5%	up	to	at	
most	20%)	without	treatment,	a	noninferiority	margin	of	20%	for	the	
efficacy	 coprimary	 endpoint	 is	 considered	 acceptable	 to	 preserve	
at	least	62%	and	up	to	70%	of	the	effect	size	under	SOC	treatment.
For	the	coprimary	efficacy	endpoint,	180	patients	will	be	evalu-
able	in	the	intent-	to-	treat	population,	giving	89%	power	to	demon-
strate	noninferiority	with	a	margin	of	20%	at	a	one-	sided	significance	
level	of	5%,	assuming	dabigatran	and	SOC	have	equivalent	effect.	If	
noninferiority	is	demonstrated,	the	coprimary	endpoints	will	subse-
quently	be	tested	for	superiority	at	a	one-	sided	level	of	0.05,	with-
out	multiplicity	correction.
For	 the	 efficacy	 coprimary	 endpoint,	 an	 intent-	to-	treat	
analysis	 will	 be	 performed	 on	 the	 randomized	 set;	 data	 will	
be	 stratified	 by	 age	 group	 using	 a	 Mantel-	Haenszel–type	
weighted	 average	 of	 differences.	 The	 safety	 coprimary	 end-
point	will	 be	 analyzed	 as	 a	 time-	to-	event	 endpoint	 using	 the	
Kaplan-	Meier	method	on	the	treated	set;	age	group	stratifica-
tion	will	not	be	used.
A	secondary	analysis	will	be	performed	to	assess	the	proportion	
of	 patients	 with	 complete	 thrombus	 resolution	 with	 no	 recurrent	
VTE	and	no	VTE-	related	death	using	age	group	as	a	 covariate.	All	
bleeding	events	and	all-	cause	mortality	will	be	analyzed	as	a	time-	
to-	event	endpoint	using	a	stratified	Cox	proportional	hazard	model.	
Components	of	the	coprimary	efficacy	endpoint	will	be	analyzed	as	
proportions	using	the	same	model	as	the	primary	analysis.	PK	and	
PD	assessments	will	include	all	treated	patients	with	a	baseline	and	
at	least	one	post-	baseline	PK/PD	measurement	set;	concentrations	
will	be	compared	descriptively	and	descriptive	statistics	will	be	cal-
culated	for	the	activated	partial	thromboplastin	time,	ecarin	clotting	
time,	and	additional	PD	assays.	In	addition,	the	PK/PD	relationship	
will	be	examined.	Other	endpoints	will	be	summarized	descriptively.
4  | DISCUSSION
Effective	treatment	of	thromboembolic	events	is	important	to	pre-
vent	significant	morbidity	and	mortality	in	children.	VTE,	for	instance,	
can	 lead	to	death	from	pulmonary	embolism,	nonlethal	pulmonary	
embolism,	recurrent	VTE,	and	post-	thrombotic	syndrome.2,7	DE	may	
provide	an	alternative	treatment	for	pediatric	VTE,	overcoming	the	
limitations	of	 the	current	SOC,	which	 include	 the	 requirement	 for	
coagulation	monitoring	 (for	VKA),	variable	PK,	 the	risk	of	heparin-	
induced	thrombocytopenia	(for	UFH),	and	parenteral	administration	
and	dependency	on	antithrombin	 levels	 (for	UFH	and	LMWH).5,6,8 
Although	data	on	DE	 for	 the	 treatment	of	VTE	are	available	 from	
adult	patients,	studies	are	still	required	in	pediatric	patients	due	to	
differences	in	organ	maturation,	coagulation	system,	and	dosing.7,10
Ease	of	administration	is	particularly	important	for	children,	who	
are	likely	to	object	to	injections	and	may	not	be	willing	or	able	to	swal-
low	capsules,	leading	to	compliance	issues.	Currently,	no	licensed	pe-
diatric	formulations	of	antithrombotic	drugs	are	available.	Therefore,	
the	pellet	and	oral	liquid	formulations	of	DE	used	in	the	current	study	
would	provide	much-	needed	child-	friendly	alternatives.
An	objective	of	the	current	study	is	to	evaluate	the	appropriate-
ness	of	the	proposed	dosing	algorithm.	Should	results	confirm	that	
it	is	appropriate,	dabigatran	levels	may	not	need	to	be	monitored	in	
children	 in	 routine	 clinical	 practice.	 Preliminary	 findings	 from	ear-
lier	phase	IIa	studies	that	assessed	the	PK	and	PD	of	single	doses	of	
DE	administered	as	an	oral	liquid	formulation	in	children	aged	0	to	
<12	years	indicated	that	the	proposed	dosing	algorithm	is	appropri-
ate	and	leads	to	comparable	exposure	between	pediatric	and	adult	
patients,	with	moderate	variability	of	plasma	concentrations.15,17 In 
addition,	the	PK/PD	relationships	are	similar	between	pediatric	and	
adult	VTE	patients.15,17	The	dosing	nomogram	is	also	being	used	in	
a	phase	III	trial	for	the	secondary	prevention	of	VTE	in	pediatric	pa-
tients	aged	0	to	<18	years	(NCT02197416).
The	current	study	is	the	result	of	an	academic–industry	partner-
ship.	Collaborations	 of	 this	 nature	 can	 provide	mutual	 benefits	 to	
both	parties,	the	pharmaceutical	company	gaining	the	knowledge	of	
TABLE  3 Secondary	and	other	endpoints
Secondary endpoints
PK	and	PD	assessments	3	days	after	start	of	treatment	(after	at	least	
six	consecutive	DE	doses)	and	after	3	days	following	any	DE	dose	
adjustment
Frequency	of	dose	adjustments,	temporary	and	permanent	
discontinuation	from	therapy	and	number	of	laboratory	monitoring	
requirements	for	dose	adjustment	during	the	treatment	phase
Frequency	of	switch	of	type	of	anticoagulation	therapy	(including	
dabigatran	to	SOC)	and	a	switch	from	an	intended	SOC	to	another	
SOC
Freedom	from	thrombus	progression	at	the	end	of	treatment	(day	
84	after	randomization	or	the	early	end	of	treatment)
Acceptability	of	an	age-	appropriate	formulation	at	end	of	treatment
All	bleeding	events
All-	cause	mortality
All	components	of	the	coprimary	efficacy	endpoints
Other endpoints
Proportion	of	patients	with	thrombus	progression,	unchanged	
thrombus,	thrombus	with	partial	regression,	and	complete	
resolution	per	treatment	group	at	day	84	after	randomization	or	at	
the	early	end	of	treatment	(whichever	comes	first)
Proportion	of	patients	with	freedom	from	recurrent	VTE	and	
freedom	from	mortality	related	to	VTE
Proportion	of	patients	with	either	complete	or	partial	thrombus	
resolution,	freedom	from	recurrent	VTE	and	freedom	from	
mortality	related	to	VTE
Acceptability	of	capsules,	pellets,	and	OLF	reconstituted	with	
flavored	or	unflavored	solvent	at	3,	21,	and	84	days	after	
randomization
DE,	dabigatran	etexilate;	OLF,	oral	liquid	formulation;	PD,	pharmacody-
namic;	 PK,	 pharmacokinetic;	 SOC,	 standard	 of	 care;	 VTE,	 venous	
thromboembolism.
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leading	experts	in	a	given	field	and	benefitting	from	their	first-	hand	
experience	 of	 routine	 clinical	 practice,	 and	 the	 academic	 parties	
receiving	funding	and	essential	resources	to	conduct	clinical	 trials.	
Collaborative	efforts	between	industry	and	academia	are	needed	for	
the	implementation	of	high-	quality,	well-	designed,	adequately	pow-
ered	trials,	which	have	previously	been	lacking	in	children	with	VTE,	
who	have	historically	received	treatment	based	on	low-	quality	evi-
dence	extrapolated	from	adult	practice.41	Having	a	clear	administra-
tive	structure	(eg,	with	a	steering	committee	and	a	data	monitoring	
committee),	like	the	one	outlined	for	the	current	study,	ensures	the	
appropriateness	of	clinical	research	conduct	for	such	collaborations.
There	 are	 several	 issues	 in	designing	 and	 conducting	 trials	 of	
antithrombotic	therapy	 in	children.	First,	dosing	must	be	adapted	
to	 the	 pediatric	 population,	 taking	 into	 account	 developmental	
changes	in	the	hemostatic	system	and	an	individual	child’s	weight	
(or	 weight	 and	 age).41	 As	 previously	 discussed,	 the	 dosing	 strat-
egy	 in	the	current	study	has	been	carefully	considered	and	 is	ex-
pected	 to	 result	 in	 safe	 and	 effective	 DE	 doses.	 Another	 major	
challenge	 in	 conducting	 large	 anticoagulant	 trials	 in	 children	 is	
the	 low	 frequency	of	 pediatric	VTE.41	 For	 example,	 slow	 recruit-
ment	was	 the	 reason	 for	early	 termination	of	 two	previous	pedi-
atric	 antithrombotic	 trials,	 PROphylaxis	 of	 ThromboEmbolism	 in	
Kids	Trial	(PROTEKT)	and	REVIparin	in	Venous	ThromboEmbolism	
(REVIVE).42	In	both	studies,	the	final	sample	size	was	not	sufficient	
to	 achieve	 the	 anticipated	 power.42	 The	 target	 enrollment	 count	
of	180	patients	in	the	current	study	is	considered	to	be	achievable	
and	will	 allow	adequate	power	 to	demonstrate	 the	noninferiority	
of	DE	versus	SOC.	To	ensure	that	the	minimum	number	of	patients	
are	enrolled,	new	sites	may	be	opened	in	additional	countries.	This	
strategy	of	 increasing	 the	number	of	participating	sites	was	used	
to	 successfully	 increase	 the	patient	 accrual	 rate	 in	 the	 feasibility	
phase	of	Kids-	DOTT,	a	multicenter,	randomized	controlled	trial	of	
shortened	(6-	week)	versus	conventional	(3-	month)	duration	of	an-
ticoagulation	for	the	treatment	of	venous	thrombosis	in	neonates,	
children,	and	young	adults.41,43
The	current	study	does	have	limitations.	Clinical	trials	are	ideally	
randomized	with	a	double-	blind	design.	Blinding	of	the	current	study	
is	not	possible	for	ethical	reasons	relating	to	the	vulnerable	patient	
population	 and	 due	 to	 the	 difficulties	 associated	 with	 comparing	
pediatric	 formulations	of	DE	with	 SOC	 that	 require	 subcutaneous	
administration	(in	the	case	of	LWMH)	or	monitoring	and	dose	adjust-
ments	(in	the	case	of	VKA).	For	example,	in	order	to	blind	the	trial,	
dummy	subcutaneous	injections	or	dummy	INR	testing	would	need	
to	be	performed	for	the	LWMH	and	VKA	comparisons,	respectively,	
which	cannot	be	justified	in	pediatric	subjects.	In	addition,	a	specific	
comparator	 is	 not	 being	 used,	making	 comparisons	more	 difficult;	
however,	the	choice	of	an	SOC	treatment	according	to	local	practice	
is	considered	to	reflect	the	real-	world	situation	well.	Another	consid-
eration	is	the	relatively	small	sample	size,	although	it	 is	considered	
to	be	sufficient	to	provide	conclusive	information	regarding	efficacy	
(VTE	resolution	and	recurrent	VTE	events),	based	on	the	complete	
resolution	rate	determined	from	historical	pediatric	data.	Lastly,	the	
4-	month	study	period	is	not	sufficient	to	evaluate	the	study	drugs’	
effects	on	prevention	of	 long-	term	complications	of	DVT,	 such	 as	
post-	thrombotic	syndrome,	which	usually	takes	at	least	1	year	to	de-
velop	following	the	DVT	event.
In	conclusion,	 findings	 from	the	current	 study,	which	 is	one	of	
the	largest	for	VTE	in	pediatric	patients,	will	provide	valuable	infor-
mation	regarding	the	efficacy	and	safety	of	DE	for	this	indication	in	
this	patient	population.
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